Insitro was last valued at $2.4B. It dates from Sep 2021. Insitro was acquired by CombinAble.AI.
One company valuation: $2.4B, dated Sep 2021.
Biotech company.
Last valuation$2.4BSep 2021The routes section explains what is realistically available for a company at this stage.
No. Insitro was acquired by CombinAble.AI Biotech firm combining automated cellular experiments and population genetics with AI to identify disease drivers and deliver targeted therapeutics; its shares do not trade independently.
The last valuation is $2.4B.
Lead investors for each round are in the funding timeline.
The closest biotechnology peers are on the competitors page.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
